ReviewMicroorganisms2025
HNP-1: From Structure to Application Thanks to Multifaceted Functions.
Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Redefining Therapies for Drug-Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design.Advanced healthcare materials · 2026Review
- The Potential of Non-Ribosomal Peptide Engineering for Creating New Antimicrobial Complexes.Molecules (Basel, Switzerland) · 2026Review
- Vitamin D-Induced Antimicrobial Peptides in Combating Viral Infections.Advances in experimental medicine and biology · 2026Review
- Scalable recombinant production of bioactive human neutrophil peptide-1 in Komagataella phaffii.AMB Express · 2025Article
- Antimicrobial peptides for anticancer and antiviral therapy: last promising update.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) are critical components of innate immunity in animals and plants, exhibiting thrilling prospectives as alternatives to traditional antibiotics due to their ability to combat pathogens without leading to resistance. Among these, Human Neutrophil Peptide-1 (HNP-1), primarily produced by human neutrophils, exhibits broad-spectrum antimicrobial activity against bacteria and viruses. However, the clinical application of HNP-1 has been hampered by challenges associated with mass production and inconsistent understanding of its bactericidal mechanisms. This review explores the structure and function of HNP-1, discussing its gene expression, distribution, immune functions and the regulatory elements controlling its production, alongside insights into its antimicrobial mechanisms and potential clinical applications as an antimicrobial agent. Furthermore, the review highlights the biosynthesis of HNP-1 using microbial systems as a cost-effective alternative to human extraction and recent studies revealing HNP-1's endogenous bactericidal mechanism. A comprehensive understanding of HNP-1's working mechanisms and production methods will pave the way for its effective clinical utilization in combating antibiotic-resistant infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.